Sheidan Organ headshot.

Sheridan A. Organ

Associate

Sheridan A. Organ

Associate

Sheridan Organ is a member of the Health Care Practice. While attaining her master’s in public health, Sheridan worked as a Public Health Law Fellow at the Center for Disease Control and Prevention with a placement at the NYC Department of Health and Mental Hygiene and as a teaching fellow at Boston University.

During law school, Sheridan was selected for the Mayo-Foley Health Law Fellowship, consisting of summer internships with the Mayo Clinic Legal Department in Rochester, Minnesota and Foley’s Boston office. During this time, she assisted attorneys at both the Mayo Clinic and Foley with a broad range of regulatory compliance and transactional matters. While in law school, Sheridan also interned at Medical Legal Partnerships Boston where she supported law and policy consultants by conducting legal research for interdisciplinary communities of care teams.

Presentations and Publications

  • Co-author, “Massachusetts: New Year, New Law — Governor Signs “An Act enhancing the market review process” (House Bill No. 5159),” Health Care Law Today (January 14, 2025)
December 2, 2025 Health Care Law Today

Digital Health Technologies Use in Clinical Trials: Support from MAHA and Defined Expectations from FDA’s Final Guidance

Digit health technologies (DHT) are a key aspect of U.S. Health & Human Services (HHS) Secretary Robert F. Kennedy Jr.’s Make America...
September 5, 2025 In the News

Foley Attorneys Contribute to American Health Law Association's Representing Physicians Handbook

Foley & Lardner LLP attorneys Jana Kolarik, Claire Marblestone, Illana Meyer, Sheridan Organ, and Kate Pamperin contributed to the Fifth Edition of the American Health Law Association's (AHLA) Representing Physician's Handbook.
A person holds an insulin pen in one hand and removes the cap with the other hand, illustrating precision and care much like chicago lawyers handle complex litigation support.
August 7, 2025 Health Care Law Today

GLP-1 Drugs: Ohio Board of Pharmacy Issues FAQs for Compounders

In spring 2025, the Food and Drug Administration (FDA) resolved and ended the GLP-1 medications shortage, subsequently releasing declaratory orders that neither outsourcing compounding pharmacies or pharmacies could compound drugs that were essentially copies of either semaglutide (available under the brand names Ozempic, Rybelsus, and Wegovy) and tirzepatide (available under the brand names Mounjaro, and Zepbound).
May 23, 2025 In the News

Foley Attorneys Publish on FDA's AI Medical Device Software Recommendations

Foley & Lardner LLP attorneys Kyle Faget, Nathan Beaver, David Rosen, and Sheridan Organ authored the MD+DI article, "FDA Outlines AI Medical Device Software Recommendations in Draft Guidance."
May 15, 2025 Health Care Law Today

“AI Policy Roadmap” Released by AdvaMed to Guide Regulators

On March 14, 2025, AdvaMed, the MedTech Association, released its AI Policy Roadmap (the Roadmap) outlining policy priorities for...
May 15, 2025 Health Care Law Today

Drug Pricing: Trump Signs “Most Favored Nation” Executive Order

On May 12, 2025, President Trump signed the second drug pricing-related Executive Order (EO) of his current administration. While...